The following is a summary of the Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Quoin Pharmaceuticals Ltd ended the year with around $10.7 million cash and marketable securities, in comparison to $14 million at the end of Q3.

• Net loss for the year was reported to be $8.7 million, which is a decrease from the $9.4 million recorded in 2022, mainly due to increase in interest income, lower professional fees, and decreased G&A costs. This was partially offset by the upward trend in R&D spending.

Business Progress:

• QNRX has achieved significant progress in clinical trials for Netherton syndrome, receiving the first-ever clinical data from its open IND with the US FDA, providing encouraging and positive results on multiple clinical endpoints.

• Quoin successfully submitted several amendments to increase the size of its studies, change the dosing frequency, and reduce eligibility age.

• 2024 is expected to be a pivotal year for Quoin Pharmaceuticals, as they plan to roll out the first FDA approved treatment for Netherton syndrome.

• The company is establishing its own infrastructure to sell their product in the US and Western Europe post approval and has entered into nine commercial partnerships covering 61 entities.

• Quoin is also focusing on potential M&A activities as part of their future growth strategy while maintaining a robust balance sheet.

More details: Quoin Pharmaceuticals IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.